Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.41 |
| ▸ | TYK2 | P29597 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | F9 | P00740 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.32 |
| ▸ | EIF4E | P06730 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13922249 | 0.92 | MAPKAPK5 (0.42) | MAPKAPK5TYK2JAK2TNFF9 | |
| SCHEMBL1685111 | 0.89 | MAPKAPK5 (0.45) | MAPKAPK5TYK2JAK2TNFF9 | |
| SCHEMBL10166432 | 0.86 | MAPKAPK5 (0.35) | MAPKAPK5CDK2KCNH2 | |
| SCHEMBL12618951 | 0.85 | MAPKAPK5 (0.47) | MAPKAPK5TYK2JAK2TNFF9 | |
| SCHEMBL10134096 | 0.84 | MAPKAPK5 (0.48) | MAPKAPK5TYK2JAK2TNFF9 | |
| SCHEMBL14162768 | 0.84 | MAPKAPK5 (0.46) | MAPKAPK5TNFF9GSK3BDAPK3 | |
| SCHEMBL1685248 | 0.80 | MAPKAPK5 (0.42) | MAPKAPK5JAK2GSK3B | |
| SCHEMBL1685105 | 0.79 | MAPKAPK5 (0.51) | MAPKAPK5F9GSK3BMKNK1EIF4E | |
| SCHEMBL10134341 | 0.79 | MAPKAPK5 (0.44) | MAPKAPK5TNFF9GSK3BDAPK3 | |
| SCHEMBL1685199 | 0.78 | MAPKAPK5 (0.41) | MAPKAPK5TNFGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008065199-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885TYK2 67/4885JAK2 1510/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885TYK2 67/4885JAK2 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.